Confo Therapeutics

Foundation date

11/06/2015

Sector

#Biotechnology - Therapeutics

Subsector

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets.

This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.

Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.

Upcoming events

Latest news

  • Cerba Research & Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

    8 hours ago

  • Novalis Biotech invests in Rarity Bioscience's ultra sensitive genomics technology

    1 day ago

  • Fat creates an ideal environment for metastatic breast tumors

    1 day ago